Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

CorpWatch Exclusives

Actavis Sued To Stop Forced Switch To New Alzheimer's Drug
by Richard SmallteacherCorpWatch Blog
September 16th, 2014
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.

Gilead Sciences Under Investigation for Over Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Big Pharma Abandons New Tuberculosis Drug Research
by Fatima HansiaCorpWatch Blog
April 1st, 2014
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Bayer CEO Says Drugs Developed For “Western Patients Who Can Afford It”
by Pratap ChatterjeeCorpWatch Blog
February 3rd, 2014
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines “for western patients who can afford it” not for the “Indian market.” The company has been critical of the Indian governments efforts to make cheap generic drugs available locally.

Bumper Year for Corporate Donations Reveals Profit Motives
by Rick CohenCorpWatch Blog
September 10th, 2013
U.S. corporations gave away $18.15 billion in charitable donations in 2012 – a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.

GlaxoSmithKline Alleged to Pay Bribes in China
by Pratap ChatterjeeCorpWatch Blog
July 15th, 2013
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.

Myriad Loses Patent to Breast Cancer Genetic Test
by Richard SmallteacherCorpWatch Blog
June 13th, 2013
Myriad Genetics has lost its right to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer. The American Civil Liberties Union (ACLU), which sued the company, claimed that the patent would limit scientific research as well as health care options for women.

Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
by Pratap ChatterjeeCorpWatch Blog
May 14th, 2013
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.

Medical Trial Data Activists Score Win Over Glaxo
by Pratap ChatterjeeCorpWatch Blog
February 7th, 2013
All data on completed medical experiments are to be made available to the general public by GlaxoSmithKline, the biggest UK pharmaceutical company. The announcement is a major win for the AllTrials campaign mounted by healthcare activists as well as researchers that has gathered widespread support.

UK Pathology Labs Suffer In Quality Under Serco Management
by Puck LoCorpWatch Blog
October 24th, 2012
Privatization of major medical laboratories from the National Hospital Service (NHS) in Britain has led to a dramatic decline in service quality, according to a “Transforming Pathology, the Serco way,” a recent report from UK-based researchers Corporate Watch.

Indian Supreme Court to Hear Novartis “Patents Versus Patients” Case
by Pratap ChatterjeeCorpWatch Blog
August 21st, 2012
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.

Pfizer Admits Bribery in Eight Countries
by Pratap ChatterjeeCorpWatch Blog
August 8th, 2012
Pharmaceutical giant Pfizer has agreed to pay a total of $60.2 million in penalties to U.S. government regulators to settle documented charges of bribery in eight countries: Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia.

Court to Hear Challenge to Myriad’s Human Gene Patent
by Pratap ChatterjeeCorpWatch Blog
July 19th, 2012
Should a private company be allowed to patent isolated human genes? A lawsuit to be heard Friday pits Myriad Genetics of Utah against the American Civil Liberties Union (ACLU). Myriad wants to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer.

Fake Drug Plague or Pharmaceutical Industry Attack on Generics?
by Pratap ChatterjeeCorpWatch Blog
June 13th, 2012
Are Africa and South East Asia just suffering from a deluge of fake medicines that is causing disease resistance to rise? Or are they also suffering from a deluge of poorly informed media articles, encouraged by the pharmaceutical industry that wants to make war on generic drugs?

Fighting Malaria: Big Pharma or Better Aid Coordination?
by Pratap ChatterjeeCorpWatch Blog
May 2nd, 2012
Why don’t drug companies invest enough money in treating malaria and tuberculosis? A recent study published in the Lancet magazine estimates that 1,238,000 people died from malaria in 2010. Surely a wonder drug that stops these diseases would be wildly profitable?

Johnson & Johnson Fined $1.2 Billion for Drug Labeling Failure
by Pratap ChatterjeeCorpWatch Blog
April 12th, 2012
Johnson & Johnson has been fined $1.2 billion in Arkansas over the sales of Risperdal, an antipsychotic drug. A circuit judge ruled that the company did not warn patients that the drug places elderly patients with dementia at an increased risk of major weight gain, possible diabetes and potential death.

Deadly Blow to Death Penalty Drugs
by Pratap ChatterjeeCorpWatch Blog
March 28th, 2012
U.S. imports of sodium thiopental have been banned by a federal judge because of the poor quality of imports. The ruling has struck a serious blow against the death penalty because of the key role the drug plays in lethal injections. Not surprisingly, the state of Texas is furious.

India Ends Bayer Monopoly, Helps Slash Prices for Life-Saving Drugs
by Pratap ChatterjeeCorpWatch Blog
March 12th, 2012
The decision by PH Kurian, the controller general of patents, designs and trademarks in India, to allow a local company to manufacture Sorafenib, a drug used to treat advanced kidney cancer and liver cancer, is a welcome move that supports the access of poor people to cheap life-saving drugs.

Grey Market Drugs: Profiting from Poorly Managed U.S. Health Care
by Terry J. AllenSpecial to CorpWatch
January 22nd, 2012
Scalpers are doing a booming business in key medical drugs by taking advantage of U.S. patients and hospitals when they are desperate for supplies from the poorly regulated $46 billion global contract-manufacturing industry.

Doctoring the Evidence: GlaxoSmithKline Pushes Depression Drug
by Shelley JofreSpecial to Corp Watch
July 30th, 2007
GlaxoSmithKline provides research funding to doctors who write favorable opinions of depression drugs for children, despite evidence from clinical trials that the medication can cause anger and even suicide.

Displaying 1-20 of 26  
Next >> 
Last Page » 
« Show Complete List »